Phase 3 Mutation Clinical Trials
16 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–16 of 16 trials
Recruiting
Phase 3
Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders
Turner SyndromeIdiopathic Short StatureShort Stature Homeobox Gene Mutation+1 more
Ascendis Pharma A/S186 enrolled11 locationsNCT07221851
Recruiting
Phase 3
A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
Lung CancerEGFRNSCLC, Stage IB-IIIA+5 more
Taiho Oncology, Inc.360 enrolled253 locationsNCT07128199
Recruiting
Phase 3
Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLC
Non-Small Cell Lung Cancer With EGFR Mutation
Instituto Nacional de Cancerologia de Mexico28 enrolled1 locationNCT05852990
Recruiting
Phase 3
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
PIK3CA Mutation
Relay Therapeutics, Inc.540 enrolled120 locationsNCT06982521
Recruiting
Phase 3
MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib
Acute Myeloid Leukemia (AML)Maintenance TherapyAllogeneic Hematopoietic Cell Transplantation (HCT)+3 more
The First Affiliated Hospital of Soochow University594 enrolled2 locationsNCT07463651
Recruiting
Phase 3
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
Servier Bio-Innovation LLC136 enrolled114 locationsNCT06127407
Recruiting
Phase 3
KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases
Mitochondrial DiseasesMaternally Inherited Diabetes and Deafness (MIDD)Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS)+1 more
Khondrion BV220 enrolled10 locationsNCT06451757
Recruiting
Phase 3
A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations
Non-Small Cell Lung Cancer With HER2- Mutations
Jiangsu HengRui Medicine Co., Ltd.300 enrolled1 locationNCT06430437
Recruiting
Phase 2Phase 3
Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer
PALB2 Gene MutationPancreatic Cancer, Advanced or MetastaticBRCA1/2 Mutation
University Health Network, Toronto10 enrolled1 locationNCT06783140
Recruiting
Phase 3
The Cancer of the Pancreas Screening-5 CAPS5)Study
Pancreas CancerPeutz-Jeghers Syndrome (PJS)Gene Mutation+2 more
Johns Hopkins University9,000 enrolled9 locationsNCT02000089
Recruiting
Phase 3
Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT
Asymptomatic Brain MetastasesDriver Mutation Positive Non-small Cell Lung Cancer
Tata Memorial Hospital190 enrolled1 locationNCT05236946
Recruiting
Phase 3
A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations
Locally Advanced or Metastatic Non-squamous NSCLCHarboring EGFR Sensitive Mutations NSCLCPreviously Untreated Systematically NSCLC
Shanghai JMT-Bio Inc.516 enrolled1 locationNCT06735391
Recruiting
Phase 3
Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1Δ11 Variant
Sleep Wake DisordersSleep Disorders, Circadian RhythmChronobiology Disorders+1 more
Vanda Pharmaceuticals60 enrolled1 locationNCT06701396
Recruiting
Phase 3
Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)
NSCLCEGFR Activating Mutation
TYK Medicines, Inc680 enrolled2 locationsNCT05382728
Recruiting
Phase 3
Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases
Brain MetastasesRadiotherapyEGFR Activating Mutation
Sun Yat-sen University232 enrolled1 locationNCT05768490
Terminated
Phase 3
Genetic Risk Information Disclosure study.
Genetic mutations predisposing to breast, ovarian or colorectal cancer and methods of disclosing that information to relatives.
The Cancer Council Victoria40 enrolled1 locationACTRN12607000316404